Frazier Life Sciences Management L.P. Acquires Shares of 1,152,456 Immatics (NASDAQ:IMTX)

Frazier Life Sciences Management L.P. acquired a new stake in Immatics (NASDAQ:IMTX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,152,456 shares of the company’s stock, valued at approximately $13,392,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Baker BROS. Advisors LP boosted its position in Immatics by 10.4% in the 1st quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock valued at $67,720,000 after buying an additional 604,545 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Immatics by 13.3% during the fourth quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after purchasing an additional 747,772 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after purchasing an additional 891,191 shares during the last quarter. Vestal Point Capital LP bought a new position in shares of Immatics during the fourth quarter worth about $22,113,000. Finally, RA Capital Management L.P. bought a new position in shares of Immatics during the first quarter worth about $18,392,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a research report on Thursday, September 5th.

Immatics Stock Performance

Shares of IMTX stock opened at $11.73 on Friday. Immatics has a one year low of $7.15 and a one year high of $13.77. The company’s 50-day simple moving average is $11.73 and its 200-day simple moving average is $11.55. The stock has a market capitalization of $993.04 million, a price-to-earnings ratio of -11.07 and a beta of 0.75.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.17. The firm had revenue of $20.19 million for the quarter, compared to analyst estimates of $12.36 million. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. As a group, research analysts forecast that Immatics will post -0.99 EPS for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.